OraSure Secures $205M Contract For OTC COVID-19 Tests
The Defense Logistics Agency has awarded OraSure Technologies Inc (NASDAQ: OSUR) a procurement contract for its InteliSwab COVID-19 Rapid Test for over-the-counter use.
OraSure Receives $205M Procurement Contract For InteliSwab From The Defense Logistics Agency To Supply Over-The-Counter Kits As Part Of National Pandemic Response
OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Defense Logistics Agency has awarded the Company a
48 Biggest Movers From Friday
Gainers
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
OraSure Technologies Announces Resignation Of CFO Roberto Cuca; Co. Has Initiated Search For Permanent CFO
OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care testing and sample collection technologies, announced that Chief Financial Officer Roberto Cuca has resigned from the Company effective September
Looking into OraSure Technologies’s Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, OraSure Technologies (NASDAQ:OSUR) earned $1.80 million, a 82.75% increase from the preceding quarter.
OraSure Stock Is Trading Lower As Q2 Earnings, Outlook Trail Estimates
OraSure Technologies Inc (NASDAQ:OSUR) reported second-quarter revenues almost doubled to $57.6 million, slightly ahead of the consensus of $56.69 million.…
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
Raymond James Maintains Outperform on OraSure Technologies, Raises Price Target to $12.5
Raymond James analyst Andrew Cooper maintains OraSure Technologies (NASDAQ:OSUR) with a Outperform and raises the price target from $11 to $12.5.